Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

Pharmacyclics, Inc. announced today that the enrollment target of 350 patients for its Phase III study using ibrutinib monotherapy versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma, (RESONATE) was achieved on April 3, 2013.

23 Apr 2013

UB researchers develop aniontransporters to trigger cancer cell apoptosis

The journal Accounts of Chemical Research, which has a profound impact on Chemistry and other related sciences, publishes on its current issue the article "Anion Transporters and Biological Systems", signed by Professor Ricardo Pérez Tomás, from the Department of Pathology and Experimental Therapy of the Faculty of Medicine at the University of Barcelona, Roberto Quesada, from the Department of Chemistry of the Sciences Faculty at the University of Burgos, and Philip A. Gale, from the University of Southampton, in the United Kingdom.

22 Apr 2013

Researchers study new ways of taking advantage of caffeine's lethal effects on cancer cells

Researchers from the University of Alberta are abuzz after using fruit flies to find new ways of taking advantage of caffeine's lethal effects on cancer cells-results that could one day be used to advance cancer therapies for people.

19 Apr 2013

New pre-clinical study suggests novel drug combination therapy for leukemia treatment

A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins.

18 Apr 2013

Discovery suggests new therapeutic target for treating dysfunctional beta cells, type 2 diabetes

Researchers at the University of California, San Diego School of Medicine have identified a previously unknown biological mechanism involved in the regulation of pancreatic islet beta cells, whose role is to produce and release insulin.

12 Apr 2013

$Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients$

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.

11 Apr 2013

Reduction in neurogenesis associated with loss of certain cognitive faculties

These results incentivise the development of targeted therapies enabling improved neurone production to alleviate cognitive decline in the elderly and reduce the cerebral lesions caused by radiotherapy.

11 Apr 2013

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia.

11 Apr 2013

Study: microRNA is designed to stop proliferation of prostate cancer cells

The most recent in a series of studies from a team at the UC Davis Comprehensive Cancer Center has shown that a single molecule is at the heart of one of the most basic survival tactics of prostate cancer cells.

10 Apr 2013

Research shows omega-3 fatty acids stop proliferation of triple-negative breast cancer cells

Researchers from Fox Chase Cancer Center have found that omega-3 fatty acids and their metabolite products slow or stop the proliferation, or growth in the number of cells, of triple-negative breast cancer cells more effectively than cells from luminal types of the disease.

10 Apr 2013

Research shows UNC1062 blocks Mer survival signaling in melanoma cells

Collaborative research presented by the University of Colorado Cancer Center, the University of North Carolina at Chapel Hill, Harvard Medical School and the University of Pittsburgh, at the American Association for Cancer Research Annual Conference, shows that the protein receptor Mer is overexpressed in melanoma and that the investigational drug UNC1062 blocks Mer survival signaling in these cells, killing them.

10 Apr 2013

MD Anderson scientists demonstrate new way to restore tumor suppression

Tumor suppression, the family business of the sibling genes p53, p63 and p73, is undermined from within by the split personalities of p63 and p73, which each produce protein forms that not only block the work of the other two genes but also shut down its own cancer-stifling fraternal twin.

10 Apr 2013

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.

9 Apr 2013

Study provides detail on cellular-level effects of anesthetics on developing brain in newborn mouse

Exposure to the anesthetic agent isoflurane increases "programmed cell death" of specific types of cells in the newborn mouse brain, reports a study in the April issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

9 Apr 2013

FDA grants Breakthrough Therapy Designation for ibrutinib as monotherapy for CLL patients

Pharmacyclics, Inc. announced today that the U.S. Food and Drug Administration has granted an additional Breakthrough Therapy Designation for the investigational oral agent ibrutinib as monotherapy for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma patients with deletion of the short arm of chromosome 17 (deletion 17p).

8 Apr 2013

AIM suppression could help prevent obesity-associated diseases

Obesity is linked to the widespread epidemics of diabetes and heart disease that plague society, but a lesser-known fact is that the weight can also lead to autoimmune disease.

5 Apr 2013

Modifiable lifestyle factors may prevent progression of Barrett's-related esophageal cancer

An estimated 20 million Americans have chronic heartburn. About 2 million of these people have Barrett's esophagus, a precancerous condition that affects the tube that carries food from the mouth to the stomach.

2 Apr 2013

Exposure to multiple estrogen-mimicking chemicals distorts hormone action

For years, scientists have been concerned about chemicals in the environment that mimic the estrogens found in the body. In study after study, researchers have found links between these "xenoestrogens" and such problems as decreased sperm viability, ovarian dysfunction, neurodevelopmental deficits and obesity.

29 Mar 2013

Data shows efficacy of MANF in neuroprotection 6-hydroxydopamine rat models of Parkinson's disease

Amarantus BioScience, Inc., a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today reported positive preclinical data for its lead therapeutic MANF in neuroprotection 6-hydroxydopamine (6-OHDA) rat models of Parkinson's disease.

28 Mar 2013

Researchers identify monoclonal antibody that directly kills lymphocytic leukemia cells

Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells.

26 Mar 2013

Apoptosis News and Research

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

UB researchers develop aniontransporters to trigger cancer cell apoptosis

Researchers study new ways of taking advantage of caffeine's lethal effects on cancer cells

New pre-clinical study suggests novel drug combination therapy for leukemia treatment

Discovery suggests new therapeutic target for treating dysfunctional beta cells, type 2 diabetes

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Reduction in neurogenesis associated with loss of certain cognitive faculties

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

Study: microRNA is designed to stop proliferation of prostate cancer cells

Research shows omega-3 fatty acids stop proliferation of triple-negative breast cancer cells

Research shows UNC1062 blocks Mer survival signaling in melanoma cells

MD Anderson scientists demonstrate new way to restore tumor suppression

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Study provides detail on cellular-level effects of anesthetics on developing brain in newborn mouse

FDA grants Breakthrough Therapy Designation for ibrutinib as monotherapy for CLL patients

AIM suppression could help prevent obesity-associated diseases

Modifiable lifestyle factors may prevent progression of Barrett's-related esophageal cancer

Exposure to multiple estrogen-mimicking chemicals distorts hormone action

Data shows efficacy of MANF in neuroprotection 6-hydroxydopamine rat models of Parkinson's disease

Researchers identify monoclonal antibody that directly kills lymphocytic leukemia cells

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News